Can Consun Pharmaceutical Group Limited (HKG:1681) Maintain Its Strong Returns?

In This Article:

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the lesson grounded in practicality, we'll use ROE to better understand Consun Pharmaceutical Group Limited (HKG:1681).

Over the last twelve months Consun Pharmaceutical Group has recorded a ROE of 20%. That means that for every HK$1 worth of shareholders' equity, it generated HK$0.20 in profit.

Check out our latest analysis for Consun Pharmaceutical Group

How Do I Calculate Return On Equity?

The formula for ROE is:

Return on Equity = Net Profit ÷ Shareholders' Equity

Or for Consun Pharmaceutical Group:

20% = CN¥465m ÷ CN¥2.5b (Based on the trailing twelve months to December 2018.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. You can calculate shareholders' equity by subtracting the company's total liabilities from its total assets.

What Does Return On Equity Signify?

ROE looks at the amount a company earns relative to the money it has kept within the business. The 'return' is the profit over the last twelve months. A higher profit will lead to a higher ROE. So, all else equal, investors should like a high ROE. Clearly, then, one can use ROE to compare different companies.

Does Consun Pharmaceutical Group Have A Good Return On Equity?

By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. Pleasingly, Consun Pharmaceutical Group has a superior ROE than the average (13%) company in the Pharmaceuticals industry.

SEHK:1681 Past Revenue and Net Income, July 21st 2019
SEHK:1681 Past Revenue and Net Income, July 21st 2019

That is a good sign. In my book, a high ROE almost always warrants a closer look. For example, I often check if insiders have been buying shares .

How Does Debt Impact ROE?

Virtually all companies need money to invest in the business, to grow profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.